3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Conditions
Breast Neoplasms
24
Neoplasm Metastasis
5
Triple Negative Breast Neoplasms
2
Recurrence
2
Ovarian Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Lymphatic Abnormalities
2
Lymphangioma, Cystic
2
Lymphangioma
2
Hyperglycemia
2
Hereditary Sensory and Autonomic Neuropathies
2
Vascular Malformations
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases, Vascular
1
Melanoma
1
Hormone Receptor Positive Breast Carcinoma
1
Head and Neck Squamous Cell Cancer
1
Head and Neck Neoplasms
1
HER2-positive Metastatic Breast Cancer
1
Genetic Diseases, Inborn
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Arteriovenous Malformations
1
Advanced HER2+Breast Cancer
1
Advanced Breast Cancer
1
Interventions
Alpelisib
2
mirdametinib
1
Injections, Intralesional
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphatic Abnormalities
×
Alpelisib
×
1 year
×
Clear all
NCT05948943
2026-06-02
EPIK-L1
Novartis
Phase 2/3
Recruiting
232 enrolled
NCT05983159
2026-05-05
TARGET-VM
Murdoch Childrens Research Institute
Phase 2
Recruiting
50 enrolled